A New First-Line Option for EGFR+ Lung Cancer

This week at the European Lung Cancer Congress, final results from the MARIPOSA trial confirmed that combining amivantamab + lazertinib can lead to longer overall survival compared to osimertinib alone.


Since 2020, osimertinib has been the global standard first-line treatment for advanced EGFR+ lung cancer—including in the UK.

What’s the situation in the UK?

  • This combination is not yet available on the NHS—but it’s currently under active NICE appraisal.

  • EGFR+ UK is fully engaged in the process, advocating to ensure UK patients aren’t left behind.

Things to Consider:

  • Administration: This is an IV treatment, starting weekly, then moving to every two weeks.

  • Side Effects: There may be more frequent side effects, particularly skin-related, which might need proactive management (like pre-emptive steroids or supportive care).

Why this matters:

This could be a major development in EGFR+ lung cancer care—but it won’t be right for everyone.

What matters most is access to choice, based on open, honest conversations about individual needs, quality of life, and treatment goals.

We remain committed to pushing for better options and equal access in the UK—because everyone deserves the best possible care.

EGFR+ UK